PE20130041A1 - Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) - Google Patents
Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23)Info
- Publication number
- PE20130041A1 PE20130041A1 PE2012001260A PE2012001260A PE20130041A1 PE 20130041 A1 PE20130041 A1 PE 20130041A1 PE 2012001260 A PE2012001260 A PE 2012001260A PE 2012001260 A PE2012001260 A PE 2012001260A PE 20130041 A1 PE20130041 A1 PE 20130041A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- loop
- fibronectin
- amino acid
- sequence
- Prior art date
Links
- 102000013264 Interleukin-23 Human genes 0.000 title abstract 4
- 108010065637 Interleukin-23 Proteins 0.000 title abstract 4
- 229940124829 interleukin-23 Drugs 0.000 title abstract 4
- 102000016359 Fibronectins Human genes 0.000 title abstract 2
- 108010067306 Fibronectins Proteins 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 150000001413 amino acids Chemical group 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 102000004338 Transferrin Human genes 0.000 abstract 1
- 108090000901 Transferrin Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 abstract 1
- 239000012581 transferrin Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Transplantation (AREA)
Abstract
SE REFIERE A UN POLIPEPTIDO QUE SE UNE A INTERLEUCINA 23 (IL-23), CON UNA SECUENCIA DE AMINOACIDOS POR LO MENOS 90% IDENTICA A LAS SEC ID Nº: 60-100; QUE COMPRENDE UN DOMINIO DECIMO DE FIBRONECTINA DE TIPO III (10FN3) EL CUAL TIENE POR LO MENOS UN BUCLE SELECCIONADO DEL BUCLE BC, DE Y FG CON UNA SECUENCIA DE AMINOACIDOS ALTERADA EN RELACION A LA SECUENCIA DEL CORRESPONDIENTE BUCLE DEL DOMINIO 10FN3 HUMANO; LA SECUENCIA DE AMINOACIDOS DEL BUCLE BC, DE O FG ES POR LO MENOS 80% IDENTICA A LAS SEC ID Nº: 2-59; ADICIONALMENTE COMPRENDE UNA O MAS FRACCIONES FARMACOCINETICAS TAL COMO ACIDO SIALICO, TRANSFERRINA, SEROALBUMINA, ENTRE OTROS Y UN CONECTOR DE CISTEINA SELECCIONADO DEL GRUPO DE AMINOACIDOS GSGC DE SEC ID Nº: 101 Y EIDKPCQ DE SEC ID Nº: 102. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHO POLIPEPTIDO ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30556610P | 2010-02-18 | 2010-02-18 | |
US33070610P | 2010-05-03 | 2010-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20130041A1 true PE20130041A1 (es) | 2013-01-28 |
Family
ID=43901183
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2012001260A PE20130041A1 (es) | 2010-02-18 | 2011-02-16 | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) |
Country Status (19)
Country | Link |
---|---|
US (2) | US8927693B2 (es) |
EP (1) | EP2536757B1 (es) |
JP (1) | JP2013520426A (es) |
KR (1) | KR20130010461A (es) |
CN (1) | CN102762591A (es) |
AR (1) | AR080229A1 (es) |
AU (1) | AU2011218243A1 (es) |
BR (1) | BR112012019881A2 (es) |
CA (1) | CA2790329A1 (es) |
CL (1) | CL2012002296A1 (es) |
EA (1) | EA201270713A1 (es) |
HK (1) | HK1179276A1 (es) |
MX (1) | MX2012009050A (es) |
PE (1) | PE20130041A1 (es) |
SG (1) | SG183215A1 (es) |
TN (1) | TN2012000372A1 (es) |
TW (1) | TWI508736B (es) |
WO (1) | WO2011103105A1 (es) |
ZA (1) | ZA201206969B (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG149004A1 (en) | 2003-12-05 | 2009-01-29 | Bristol Myers Squibb Co | Inhibitors of type 2 vascular endothelial growth factor receptors |
EP2727936B1 (en) | 2006-11-22 | 2016-09-07 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
WO2009102421A2 (en) | 2008-02-14 | 2009-08-20 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
PE20091931A1 (es) | 2008-05-22 | 2009-12-31 | Bristol Myers Squibb Co | Proteinas de dominio de armazon basadas en fibronectina multivalentes |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
TW201138808A (en) * | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
CN103180339B (zh) | 2010-05-26 | 2016-04-27 | 百时美施贵宝公司 | 具有改善的稳定性的基于纤连蛋白的支架蛋白质 |
JP6126532B2 (ja) | 2010-11-04 | 2017-05-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗il−23抗体 |
CN103380143B (zh) | 2010-12-22 | 2016-01-06 | 百时美施贵宝公司 | 结合il-23的基于纤连蛋白的支架结构域蛋白质 |
SI2697257T1 (sl) | 2011-04-13 | 2017-02-28 | Bristol-Myers Squibb Company | FC fuzijski proteini, ki vsebujejo nove linkerje ali razmestitve |
US20140187488A1 (en) | 2011-05-17 | 2014-07-03 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
EP2710382B1 (en) | 2011-05-17 | 2017-10-18 | Bristol-Myers Squibb Company | Improved methods for the selection of binding proteins |
JP2015504038A (ja) | 2011-10-31 | 2015-02-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 低減した免疫原性を有するフィブロネクチン結合ドメイン |
EP2773964A4 (en) * | 2011-11-03 | 2015-06-24 | Stc Biolog Inc | METHOD FOR DETERMINING THE PHARMACOLOGICAL PROPERTIES OF RECOMBINANT PROTEINS |
MX368653B (es) | 2012-05-03 | 2019-10-10 | Boehringer Ingelheim Int | Anticuerpos anti-il-23p19. |
ES2879387T3 (es) | 2012-09-13 | 2021-11-22 | Bristol Myers Squibb Co | Proteínas de dominio de armazón a base de fibronectina que se unen a miostatina |
CZ304514B6 (cs) | 2012-11-23 | 2014-06-11 | Biotechnologický Ústav Av Čr, V.V.I. | Polypeptidy pro léčbu autoimunitních chorob založenou na blokaci receptoru pro lidský cytokin IL-23 |
US20150361159A1 (en) | 2013-02-01 | 2015-12-17 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins |
ES2814558T3 (es) * | 2013-02-06 | 2021-03-29 | Bristol Myers Squibb Co | Proteínas de dominio de fibronectina tipo III con solubilidad mejorada |
ES2645634T3 (es) | 2013-02-12 | 2017-12-07 | Bristol-Myers Squibb Company | Métodos de replegado de proteínas a elevado pH |
KR20150062352A (ko) * | 2013-11-29 | 2015-06-08 | 일진엘이디(주) | 유전체층을 가진 발광 다이오드 |
IL275497B (en) * | 2014-03-20 | 2022-09-01 | Bristol Myers Squibb Co | Serum proteins with type iii fibronectin binding domains |
US10507241B2 (en) | 2014-07-24 | 2019-12-17 | Boehringer Ingelheim International Gmbh | Biomarkers useful in the treatment of IL-23A related diseases |
TWI711629B (zh) | 2014-09-03 | 2020-12-01 | 德商包林格因蓋爾漢國際股份有限公司 | 靶向IL-23A與TNF-α之化合物及其用途 |
CN108884147B (zh) | 2015-09-23 | 2024-02-27 | 百时美施贵宝公司 | 结合磷脂酰肌醇蛋白聚糖3的基于纤连蛋白的支架分子 |
KR20180056701A (ko) | 2015-09-23 | 2018-05-29 | 브리스톨-마이어스 스큅 컴퍼니 | 패스트-오프 레이트 혈청 알부민 결합 피브로넥틴 유형 iii 도메인 |
WO2017115828A1 (ja) * | 2015-12-29 | 2017-07-06 | 国立大学法人東京工業大学 | 標的結合ペプチドの安定化方法 |
TW201842929A (zh) * | 2017-05-03 | 2018-12-16 | 美商必治妥美雅史谷比公司 | 結合至肌肉生長抑制素以纖維連接蛋白為主之支架結構域蛋白質的穩定調配物 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US5672502A (en) | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
EP0752248B1 (en) | 1992-11-13 | 2000-09-27 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
EP0971946B1 (en) | 1997-01-21 | 2006-07-05 | The General Hospital Corporation | Selection of proteins using rna-protein fusions |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US7115396B2 (en) * | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
EP1268544A2 (en) | 2000-03-31 | 2003-01-02 | Institut Pasteur | Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
CA2416219C (en) | 2000-07-11 | 2016-10-11 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
EP2141243A3 (en) * | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US20070178082A1 (en) | 2002-11-08 | 2007-08-02 | Ablynx N.V. | Stabilized single domain antibodies |
SG149004A1 (en) | 2003-12-05 | 2009-01-29 | Bristol Myers Squibb Co | Inhibitors of type 2 vascular endothelial growth factor receptors |
PL1729795T3 (pl) | 2004-02-09 | 2016-08-31 | Human Genome Sciences Inc | Białka fuzyjne albuminy |
CN1317389C (zh) * | 2004-09-02 | 2007-05-23 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 抑制纤连蛋白表达的反义寡核苷酸的结构和用途 |
US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
DE102006032337A1 (de) | 2006-07-12 | 2008-01-17 | BSH Bosch und Siemens Hausgeräte GmbH | Verfahren zur Steuerung eines Schleuderablaufes einer Waschmaschine und zur Durchführung des Verfahrens geeignete Waschmaschine |
EP2727936B1 (en) | 2006-11-22 | 2016-09-07 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
BRPI0807710B1 (pt) * | 2007-02-23 | 2021-12-14 | Merck Sharp & Dohme Corp | Anticorpos que se ligam a il-23p19 e il-23 humana, anticorpo, ácido nucleico isolado, vetor de expressão, célula hospedeira microbiana, método de produção de um polipeptídeo e composição farmacêutica |
EP2056838B1 (en) * | 2007-02-28 | 2013-09-25 | Merck Sharp & Dohme Corp. | Combination therapy for treatment of immune disorders |
CL2008003561A1 (es) | 2007-11-30 | 2010-02-05 | Glaxo Group Ltd | Construccion de union a il - 13 que comprende a lo menos un dominio simple (dab) de anticuerpo injertado en un anticuerpo monoclonal ( mabdab); polinucleotido y celula huesped; procedimiento para preparar la construccion; composicion farmaceutica que la comprende y uso para tratar cancer o enfermedades inflamatorias. |
EA201000979A1 (ru) * | 2007-12-27 | 2011-02-28 | Новартис Аг | Улучшенные связывающие молекулы на основе фибронектина и их применение |
WO2009102421A2 (en) | 2008-02-14 | 2009-08-20 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
PT2274331E (pt) * | 2008-05-02 | 2014-02-27 | Novartis Ag | Moléculas de ligação baseadas em fibronectina melhoradas e suas utilizações |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
EA201101572A1 (ru) | 2009-04-27 | 2012-05-30 | Новартис Аг | Композиции и способы применения терапевтических антител, специфичных в отношении субъединицы бета1 рецептора il-12 |
-
2011
- 2011-02-16 KR KR1020127024171A patent/KR20130010461A/ko not_active Application Discontinuation
- 2011-02-16 AU AU2011218243A patent/AU2011218243A1/en not_active Abandoned
- 2011-02-16 WO PCT/US2011/024959 patent/WO2011103105A1/en active Application Filing
- 2011-02-16 US US13/579,204 patent/US8927693B2/en active Active
- 2011-02-16 JP JP2012553974A patent/JP2013520426A/ja active Pending
- 2011-02-16 MX MX2012009050A patent/MX2012009050A/es active IP Right Grant
- 2011-02-16 PE PE2012001260A patent/PE20130041A1/es not_active Application Discontinuation
- 2011-02-16 CN CN2011800100540A patent/CN102762591A/zh active Pending
- 2011-02-16 EA EA201270713A patent/EA201270713A1/ru unknown
- 2011-02-16 SG SG2012058517A patent/SG183215A1/en unknown
- 2011-02-16 CA CA2790329A patent/CA2790329A1/en not_active Abandoned
- 2011-02-16 EP EP11708608.2A patent/EP2536757B1/en active Active
- 2011-02-16 BR BR112012019881A patent/BR112012019881A2/pt not_active IP Right Cessation
- 2011-02-18 AR ARP110100518A patent/AR080229A1/es unknown
- 2011-02-18 TW TW100105496A patent/TWI508736B/zh not_active IP Right Cessation
-
2012
- 2012-07-23 TN TNP2012000372A patent/TN2012000372A1/en unknown
- 2012-08-17 CL CL2012002296A patent/CL2012002296A1/es unknown
- 2012-09-17 ZA ZA2012/06969A patent/ZA201206969B/en unknown
-
2013
- 2013-06-10 HK HK13106833.3A patent/HK1179276A1/xx not_active IP Right Cessation
-
2014
- 2014-11-25 US US14/553,379 patent/US9714281B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US9714281B2 (en) | 2017-07-25 |
SG183215A1 (en) | 2012-09-27 |
KR20130010461A (ko) | 2013-01-28 |
TN2012000372A1 (en) | 2014-01-30 |
CL2012002296A1 (es) | 2013-01-11 |
EP2536757A1 (en) | 2012-12-26 |
TWI508736B (zh) | 2015-11-21 |
EP2536757B1 (en) | 2015-03-25 |
WO2011103105A1 (en) | 2011-08-25 |
ZA201206969B (en) | 2015-06-24 |
TW201130501A (en) | 2011-09-16 |
BR112012019881A2 (pt) | 2017-06-27 |
CA2790329A1 (en) | 2011-08-25 |
CN102762591A (zh) | 2012-10-31 |
US20130012436A1 (en) | 2013-01-10 |
AR080229A1 (es) | 2012-03-21 |
AU2011218243A1 (en) | 2012-10-04 |
JP2013520426A (ja) | 2013-06-06 |
MX2012009050A (es) | 2012-09-07 |
US8927693B2 (en) | 2015-01-06 |
US20150274806A1 (en) | 2015-10-01 |
HK1179276A1 (en) | 2013-09-27 |
EA201270713A1 (ru) | 2013-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20130041A1 (es) | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) | |
PE20181923A1 (es) | Neoantigenos y metodos de su uso | |
PE20180487A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos y de soportes para el uso en la inmunoterapia contra el carcinoma colorrectal y otros tipos de cancer | |
PE20142451A1 (es) | Composiciones de conjugados de xten y metodos para realizar las mismas | |
ECSP15042898A (es) | Péptidos y composiciones para el tratamiento de daño articular | |
AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
AR081454A1 (es) | Proteinas de dominio de armazon basadas en fibronectina que se unen a pcsk9 (proproteina convertasa subtilisina kexina 9) | |
PE20161442A1 (es) | Proteinas quimericas tipo fosfatasa alcalina | |
UA120917C2 (uk) | Химерний білок фактора viii та його застосування | |
PE20170771A1 (es) | Composiciones y metodos de uso para tratar trastornos metabolicos | |
PE20230321A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer | |
CL2013003416A1 (es) | Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa. | |
AR093903A1 (es) | Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad | |
EA201792245A1 (ru) | Биоконъюгаты и их применения | |
ES2545457T3 (es) | Vacunas de péptidos para cánceres que expresan los polipéptidos DEPDC1 | |
CL2017001883A1 (es) | Compuestos antisenescentes y usos de los mismos | |
AR092076A1 (es) | Proteinas homodimericas | |
PE20160507A1 (es) | Diferenciacion de celulas madre mesenquimales | |
ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
CY1118856T1 (el) | Εμβολιο pcsk9 | |
GT201700224A (es) | Proteína de unión a rgma y su uso | |
AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
EA201791238A1 (ru) | Способы и композиции, в которых используются варианты полипептидов klotho | |
EA201491277A1 (ru) | Противораковый слитый белок | |
CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |